Anika Therapeutics (NASDAQ:ANIK) Issues Quarterly Earnings Results

Anika Therapeutics (NASDAQ:ANIK) released its earnings results on Friday. The biotechnology company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.13), FiscalAI reports. The company had revenue of $30.59 million for the quarter, compared to the consensus estimate of $29.44 million. Anika Therapeutics had a positive return on equity of 0.20% and a negative net margin of 3.14%.

Here are the key takeaways from Anika Therapeutics’ conference call:

• Revenue rose 10% to $30.6 million, with commercial revenue up 17% to a record $14 million and OEM revenue up 5%. Integrity grew more than 30% year over year, while international OA pain management revenue increased 19%.
• Anika raised its 2026 total revenue growth outlook to 6%–10% from 5%–10% and its adjusted EBITDA margin outlook to 15%–17% from 13%–17%. The outlook reflects stronger expected OEM growth, partly offset by a lower commercial growth range amid slower summer elective procedures.
• Gross margin improved to 62% from 56% a year ago, and adjusted EBITDA increased to $5.1 million from $0.9 million. The company generated $8.4 million in quarterly operating cash and ended September with $45 million in cash.
• Anika signed a new 10-year Hyvisc distribution agreement that includes higher transfer pricing, royalties, increased minimum purchases, and $8 million in upfront and volume-based payments. The $4 million upfront payment is expected in the first quarter of 2027.
• The FDA notified Anika that the Hyalofast U.S. PMA is not approvable, primarily because of the clinical data submitted; the company is evaluating regulatory pathways and potential additional evidence requirements. Separately, Anika expects to submit the Cingal NDA before the end of 2027, following completion of bioequivalence-study enrollment and ongoing CMC work.

Anika Therapeutics Price Performance

ANIK stock opened at $14.55 on Friday. The company’s 50 day simple moving average is $20.38 and its 200-day simple moving average is $16.25. The firm has a market capitalization of $194.68 million, a P/E ratio of -53.89, a P/E/G ratio of 13.86 and a beta of 0.21. Anika Therapeutics has a 52-week low of $9.01 and a 52-week high of $22.88.

More Anika Therapeutics News

Here are the key news stories impacting Anika Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 10% year over year to $30.59 million, beating the cited analyst estimate of $29.44 million. Commercial-channel revenue grew 17%, with Integrity revenue up more than 30%. Anika Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Anika raised the lower end of its 2026 revenue guidance and increased its adjusted EBITDA outlook. It forecast revenue of $119.6 million to $124.1 million, a range that includes the $121.6 million consensus estimate. Anika Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company secured a new 10-year Hyvisc partnership with improved economics and reintroduced a Hyaff product for non-orthopedic original-equipment-manufacturer customers, offering potential longer-term commercial support. Anika Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Adjusted EPS was reported at $0.29, above Zacks’ $0.17 estimate, while the cited results also show a GAAP loss of $0.02 per share. Analyst estimates differ across reports, making the earnings comparison mixed. Anika Therapeutics Beats Q3 Earnings and Revenue Estimates
• Negative Sentiment: The GAAP loss and reported EPS misses against some analyst benchmarks may have weighed on sentiment, despite the revenue beat and stronger adjusted-EPS comparison. Anika Therapeutics GAAP EPS and Revenue Results

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. B. Riley Financial started coverage on shares of Anika Therapeutics in a research report on Friday, September 18th. They issued a “buy” rating and a $23.00 price target for the company. Zacks Research downgraded Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Wall Street Zen raised shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anika Therapeutics in a research note on Monday, September 21st. Finally, Barrington Research set a $21.00 price target on Anika Therapeutics in a research report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $22.00.

About Anika Therapeutics

Anika Therapeutics, Inc develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid.

Anika’s orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid.